Stephen Opat - Concepedia

Author

Stephen Opat

Also Known As

Nasia Safdar, S Opat, S S Opat, S. Opat, S. S Opat, S. S. Opat, S.S. Opat, Stephen Opat, Stephen S Opat, Stephen S. Opat

355

Publications

10.8K

Citations

H-Index

Concepts

All Affiliations

Monash University Monash Health Peter MacCallum Cancer Centre The University of Melbourne Concord Repatriation General Hospital

About

Stephen Opat is an author at Monash University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	33	2.6K
2	Health Sciences	11	11	999
3	Allergy	2	2	154
4	Public Health	1	1	17
5	Cell Biology	1	1	15

Stephen Opat

Publications

9.7K

Citations

H-Index

Page 1

	Year	Citations
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions Valentin Goede, Kirsten Fischer, Raymonde Busch, New England Journal of Medicine	2014	1.5K
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, New England Journal of Medicine	2019	816
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma Robert Marcus, Andrew Davies, Kiyoshi Ando, New England Journal of Medicine	2017	764
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, The Lancet Oncology Lymphoid NeoplasiaOncologyMalignant Blood DisorderRefractory Follicular LymphomaDermatology	2020	556
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study Constantine S. Tam, Stephen Opat, Shirley D’Sa, Blood	2020	432
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL Constantine S. Tam, Judith Trotman, Stephen Opat, Blood	2019	355
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma Robert Kridel, Barbara Meissner, Sanja Rogić, Blood	2011	332
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunology	2020	319
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaZanubrutinib Versus BendamustineMedicineHematology	2022	256

Page 1